![Marc Berthon](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Marc Berthon
Keine laufenden Positionen mehr
Karriereverlauf von Marc Berthon
Ehemalige bekannte Positionen von Marc Berthon
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Urogene SA
![]() Urogene SA Miscellaneous Commercial ServicesCommercial Services Urogene is a urology-focused biopharmaceutical company engaged in the development of small molecule drugs for the treatment of: Lower Urinary Tract Dysfunctions such as overactive bladder and stress urinary incontinence, Prostate and Bladder Cancers. They have the expertise to set-up and manage preclinical and clinical development plans in these therapeutic areas. Its objective is to provide innovative candidates with clinical proof-of-concept of efficacy and safety. Partnerships with key players in the urology field will be proposed for late-stage clinical development and commercialization. Besipirdine, in-licensed from Aventis, is now reaching that stage. It is a potential novel first-in-class oral treatment for Overactive Bladder (OAB) currently in Phase II development. Development is planned in additional indications including Interstitial Cystitis (IC) and Stress-related Urinary Incontinence (SUI). Besipirdine represents a potential breakthrough and novel blockbuster product in OAB, SUI, mixed incontinence and IC. | Public Communications Contact | - | 17.10.2012 |
Statistik
International
Frankreich | 2 |
Operativ
Public Communications Contact | 1 |
Sektoral
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Urogene SA
![]() Urogene SA Miscellaneous Commercial ServicesCommercial Services Urogene is a urology-focused biopharmaceutical company engaged in the development of small molecule drugs for the treatment of: Lower Urinary Tract Dysfunctions such as overactive bladder and stress urinary incontinence, Prostate and Bladder Cancers. They have the expertise to set-up and manage preclinical and clinical development plans in these therapeutic areas. Its objective is to provide innovative candidates with clinical proof-of-concept of efficacy and safety. Partnerships with key players in the urology field will be proposed for late-stage clinical development and commercialization. Besipirdine, in-licensed from Aventis, is now reaching that stage. It is a potential novel first-in-class oral treatment for Overactive Bladder (OAB) currently in Phase II development. Development is planned in additional indications including Interstitial Cystitis (IC) and Stress-related Urinary Incontinence (SUI). Besipirdine represents a potential breakthrough and novel blockbuster product in OAB, SUI, mixed incontinence and IC. | Commercial Services |
- Börse
- Insiders
- Marc Berthon
- Erfahrung